Characteristic | Low expression of TM4SF19 | High expression of TM4SF19 | p |
n | 207 | 207 | |
T stage, n (%) |
|
| 0.003 |
T1 | 3 (0.8%) | 2 (0.5%) |
|
T2 | 75 (19.7%) | 44 (11.6%) |
|
T3 | 83 (21.8%) | 113 (29.7%) |
|
T4 | 28 (7.4%) | 32 (8.4%) |
|
N stage, n (%) |
|
| 0.103 |
N0 | 124 (33.5%) | 115 (31.1%) |
|
N1 | 19 (5.1%) | 27 (7.3%) |
|
N2 | 38 (10.3%) | 39 (10.5%) |
|
N3 | 1 (0.3%) | 7 (1.9%) |
|
M stage, n (%) |
|
| 0.209 |
M0 | 119 (55.9%) | 83 (39%) |
|
M1 | 4 (1.9%) | 7 (3.3%) |
|
Pathologic stage, n (%) |
|
| 0.005 |
Stage I | 3 (0.7%) | 1 (0.2%) |
|
Stage II | 80 (19.4%) | 50 (12.1%) |
|
Stage III | 61 (14.8%) | 81 (19.7%) |
|
Stage IV | 61 (14.8%) | 75 (18.2%) |
|
Radiation therapy, n (%) |
|
| 0.194 |
No | 182 (46.9%) | 185 (47.7%) |
|
Yes | 14 (3.6%) | 7 (1.8%) |
|
Primary therapy outcome, n (%) |
|
| <0.001 |
PD | 21 (5.9%) | 49 (13.7%) |
|
SD | 13 (3.6%) | 18 (5%) |
|
PR | 11 (3.1%) | 11 (3.1%) |
|
CR | 133 (37.3%) | 101 (28.3%) |
|
Gender, n (%) |
|
| 0.264 |
Female | 49 (11.8%) | 60 (14.5%) |
|
Male | 158 (38.2%) | 147 (35.5%) |
|
Race, n (%) |
|
| <0.001 |
Asian | 36 (9.1%) | 8 (2%) |
|
Black or African American | 11 (2.8%) | 12 (3%) |
|
White | 151 (38%) | 179 (45.1%) |
|
Age, n (%) |
|
| 0.921 |
≤70 | 118 (28.5%) | 116 (28%) |
|
>70 | 89 (21.5%) | 91 (22%) |
|
Weight, n (%) |
|
| 0.437 |
≤80 | 107 (28.8%) | 98 (26.4%) |
|
>80 | 79 (21.3%) | 87 (23.5%) |
|
Height, n (%) |
|
| 0.351 |
≤170 | 85 (23.3%) | 73 (20%) |
|
>170 | 100 (27.4%) | 107 (29.3%) |
|
BMI, n (%) |
|
| 0.128 |
≤25 | 85 (23.4%) | 68 (18.7%) |
|
>25 | 99 (27.2%) | 112 (30.8%) |
|
Histologic grade, n (%) |
|
| <0.001 |
High Grade | 186 (45.3%) | 204 (49.6%) |
|
Low Grade | 19 (4.6%) | 2 (0.5%) |
|
Subtype, n (%) |
|
| <0.001 |
Non-Papillary | 115 (28.1%) | 160 (39.1%) |
|
Papillary | 90 (22%) | 44 (10.8%) |
|
Lymphovascular invasion, n (%) |
|
| 0.680 |
No | 67 (23.7%) | 63 (22.3%) |
|
Yes | 74 (26.1%) | 79 (27.9%) |
|
Smoker, n (%) |
|
| 0.632 |
No | 57 (14.2%) | 52 (13%) |
|
Yes | 143 (35.7%) | 149 (37.2%) |
|
OS event, n (%) |
|
| <0.001 |
Alive | 133 (32.1%) | 98 (23.7%) |
|
Dead | 74 (17.9%) | 109 (26.3%) |
|
DSS event, n (%) |
|
| 0.002 |
Alive | 152 (38%) | 122 (30.5%) |
|
Dead | 48 (12%) | 78 (19.5%) |
|
PFI event, n (%) |
|
| 0.007 |
Alive | 131 (31.6%) | 103 (24.9%) |
|
Dead | 76 (18.4%) | 104 (25.1%) |
|
Age, median (IQR) | 68 (59, 75) | 69 (61.5, 76) | 0.223 |